当前位置: X-MOL 学术Toxicol. Res. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Novel renal biomarkers show that creatine supplementation is safe: a double-blind, placebo-controlled randomized clinical trial.
Toxicology Research ( IF 2.1 ) Pub Date : 2020-05-13 , DOI: 10.1093/toxres/tfaa028
José de Oliveira Vilar Neto 1, 2 , Carlos Alberto da Silva 2 , Gdayllon Cavalcante Meneses 1, 3 , Daniel Vieira Pinto 1 , Luciana Catunda Brito 2 , Said Goncalves da Cruz Fonseca 3 , Renata de Sousa Alves 3 , Alice Maria Costa Martins 3 , Cláudio de Oliveira Assumpção 2 , Elizabeth De Francesco Daher 1
Affiliation  

The aim of this study was to evaluate the impact of creatine supplementation (CS) on renal function in young, healthy, and active subjects. We used a randomized, double-blind, placebo-controlled clinical trial as the study design. Thirty-six healthy male university students were recruited and divided into three groups: group placebo, group G3 (3 g/day of CS), and group G5 (5 g/day of CS). To assess renal function, new kidney biomarkers, kidney injury molecule-1 (KIM-1) and monocyte chemoattractant protein-1 (MCP-1), were quantified. Serum albumin, serum creatinine, serum urea, estimated glomerular filtration rate (eGFR), proteinuria, and albuminuria were also measured. All groups were evaluated at two times: prior CS or placebo (pre) and after 35 days on CS or placebo (post). After 35 days of intervention, all characteristics were maintained without significant difference (P > 0.05) between the groups, including serum creatinine, eGFR, and more sensitive kidney biomarker concentrations (KIM-1 and MCP-1). The paired analysis showed that the supplemented groups (G3 and 5G) had increased serum creatinine and decreased eGFR levels (P < 0.05). However, the values were still within the normal reference range. In conclusion, the results of renal function evaluation did not show any difference between the evaluated groups. Increased serum creatinine and decreased eGFR levels in CS groups can be explained by increased creatine stores and metabolism, since creatinine is a by-product of creatine metabolism. These findings indicate that the use of CS at doses of 3 g and 5 g/day for a short period (35 days) is safe and did not impair the kidneys or renal function in young healthy subjects.

中文翻译:

新型肾脏生物标志物显示肌酸补充是安全的:一项双盲,安慰剂对照的随机临床试验。

这项研究的目的是评估肌酸补充剂(CS)对年轻,健康和活跃受试者肾功能的影响。我们使用了一项随机,双盲,安慰剂对照的临床试验作为研究设计。招募了36名健康的男性大学生,并将其分为三组:安慰剂组,G3组(CS每天3克)和G5组(CS每天5克)。为了评估肾脏功能,对新的肾脏生物标志物,肾脏损伤分子1(KIM-1)和单核细胞趋化蛋白1(MCP-1)进行了定量。还测量了血清白蛋白,血清肌酐,血清尿素,估计的肾小球滤过率(eGFR),蛋白尿和蛋白尿。所有组均进行两次评估:既往CS或安慰剂(治疗前)和35天后CS或安慰剂(治疗后)。经过35天的干预,P  > 0.05),包括血清肌酐,eGFR和更敏感的肾脏生物标志物浓度(KIM-1和MCP-1)。配对分析显示,补充组(G3和5G)的血清肌酐水平升高,eGFR水平降低(P <0.05)。但是,这些值仍在正常参考范围内。总之,肾功能评估的结果在评估组之间没有任何差异。CS组血清肌酐升高和eGFR降低可通过肌酸储存和代谢增加来解释,因为肌酐是肌酸代谢的副产物。这些发现表明,短期(35天)以3 g和5 g /天的剂量使用CS是安全的,并且不会损害年轻健康受试者的肾脏或肾功能。
更新日期:2020-05-13
down
wechat
bug